Ravgen specializes in non-invasive prenatal diagnostic testing, leveraging advanced technologies to analyze fetal DNA present in maternal blood. Their innovative approach allows for early testing, starting as early as five weeks gestation, by utilizing a simple blood sample from the mother and a swab from the alleged father. The company offers a range of tests, including those for single gene disorders and chromosomal abnormalities, such as cystic fibrosis (CF), spinal muscular atrophy (SMA), and sickle cell anemia. Their proprietary technology enhances the detection of fetal DNA, enabling accurate assessments of conditions like Down syndrome by identifying the presence of an extra copy of chromosome 21.

The foundation of Ravgen's technology lies in its ability to increase the concentration of fetal DNA in maternal blood samples, which is critical for the accuracy of their non-invasive tests. This advancement has led to the development of patented methodologies that prioritize safety and ease of use, requiring only a blood draw from the mother. Ravgen's commitment to scientific rigor is reflected in its numerous publications in prestigious medical journals, underscoring the credibility and reliability of their testing methods. The company is led by Dr. Ravinder Dhallan, whose extensive background in biomedical engineering and clinical research has been instrumental in shaping Ravgen's innovative strategies and technologies.

United States

Specializing in non-invasive prenatal genetic testing and paternity testing, Ravgen is focused on developing non-invasive prenatal diagnostic tests based on fetal DNA present in maternal blood. Diagnose single gene disorders, such as cystic fibrosis, sickle cell anemia and Downs syndrome, establish paternity and more early on in pregnancy.

Ravgen

Company Details